Panacea Index Logo

Command Palette

Search for a command to run...

A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.

Prostate cancer and prostatic diseases
September 1, 2019
Stephen J Freedland et al. (11 authors)
Journal ArticleMulticenter StudyRandomized Controlled TrialResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tHuman StudyClinical
Study Details

Study Goal

The researchers aimed to test whether a low-carbohydrate diet (LCD) combined with walking could mitigate metabolic disturbances caused by androgen deprivation therapy (ADT) in prostate cancer patients.

Results Summary

The LCD/walking intervention showed significant improvements in weight loss, insulin resistance, hemoglobin A1c, HDL, and triglycerides at 3 months, with some benefits (weight loss and HDL) persisting at 6 months. However, the primary outcome of insulin resistance reduction at 6 months was not statistically significant, likely due to the small sample size and early study termination.

Population

Prostate cancer patients initiating androgen deprivation therapy (ADT).

Effective Dosage

≤20g carbohydrate/day plus walking (≥30 min for ≥5 days/week).

Duration

6 months.

Interactions

None mentioned.

Extracted Claims (16)
InterventionDirectionEndpointPopulationDosageImpactClaim #
low-carbohydrate diet (LCD) plus walking
decrease
insulin resistance
prostate cancer (PCa) patients initiating ADT
4%
reduced
#1
control
increase
insulin resistance
prostate cancer (PCa) patients initiating ADT
36%
increased
#2
LCD/walking
decrease
weight
prostate cancer (PCa) patients initiating ADT
7.8kg
significantly lost
#3
LCD/walking
decrease
insulin resistance
prostate cancer (PCa) patients initiating ADT
↑36%
improved
#4
LCD/walking
decrease
hemoglobin A1c
prostate cancer (PCa) patients initiating ADT
↓3.3%
improved
#5
LCD/walking
increase
high-density lipoprotein (HDL)
prostate cancer (PCa) patients initiating ADT
↑13%
improved
#6
LCD/walking
decrease
triglyceride
prostate cancer (PCa) patients initiating ADT
↓37%
improved
#7
LCD/walking
decrease
weight loss
prostate cancer (PCa) patients initiating ADT
10.6kg
remained significant
#8
LCD/walking
increase
HDL
prostate cancer (PCa) patients initiating ADT
↑27%
remained significant
#9
LCD/walking
no change
total body bone mineral count
prostate cancer (PCa) patients initiating ADT
-
preserved
#10
LCD/walking
decrease
fat mass
prostate cancer (PCa) patients initiating ADT
-
reduced
#11
LCD/walking
decrease
lean mass
prostate cancer (PCa) patients initiating ADT
-
reduced
#12
LCD/walking
decrease
percent body fat
prostate cancer (PCa) patients initiating ADT
-
reduced
#13
LCD/walking
no change
PSA
prostate cancer (PCa) patients initiating ADT
-
no differences
#14
LCD/walking
no change
insulin sensitivity
prostate cancer (PCa) patients initiating ADT
-
did not improve
#15
LCD/walking
decrease
insulin resistance
prostate cancer (PCa) patients initiating ADT
-
reduced
#16
Abstract

PURPOSE: The objective of this study was to test a low-carbohydrate diet (LCD) plus walking to reduce androgen deprivation therapy (ADT)-induced metabolic disturbances. MATERIALS AND METHODS: This randomized multi-center trial of prostate cancer (PCa) patients initiating ADT was designed to compare an LCD (≤20g carbohydrate/day) plus walking (≥30 min for ≥5 days/week) intervention vs. control advised to maintain usual diet and exercise patterns. Primary outcome was change in insulin resistance by homeostatic model assessment at 6 months. To detect 20% reduction in insulin resistance, 100 men were required. The study was stopped early after randomizing 42 men due to slow accrual. Secondary outcomes included weight, body composition, lipids, and prostate-specific antigen (PSA). Changes from baseline were compared between arms using rank-sum tests. RESULTS: At 6 months, LCD/walking reduced insulin resistance by 4% vs. 36% increase in control (p = 0.13). At 3 months, vs. control, LCD/walking arm significantly lost weight (7.8kg; p<0.001), improved insulin resistance (↑36%; p = 0.015), hemoglobin A1c (↓3.3%; p = 0.01), high-density lipoprotein (HDL) (↑13%; p = 0.004), and triglyceride (↓37%; p = 0.036). At 6 months, weight loss (10.6kg; p<0.001) and HDL (↑27%; p = 0.003) remained significant. LCD/walking preserved total body bone mineral count (p = 0.025), reduced fat mass (p = 0.002), lean mass (p = 0.036), and percent body fat (p = 0.004). There were no differences in PSA. Limitations include the effect of LCD, weight loss vs. walking instruction are indistinguishable, and small sample size. CONCLUSIONS: In an underpowered study, LCD/walking did not improve insulin sensitivity at 6 months. Given most secondary outcomes were improved at 3 months with some remaining improved at 6 months and a secondary analysis showed that LCD/walking reduced insulin resistance over the study, supporting future larger studies of LCD/walking intervention to reduce ADT-induced disturbances.

Medical Subject Headings (MeSH)
AgedAndrogen AntagonistsBody CompositionBody WeightDiet, Carbohydrate-RestrictedHealthy LifestyleHumansMaleMetabolic SyndromeMiddle AgedProstatic NeoplasmsTreatment OutcomeWalkingWeight Loss
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality65/10
Citation Metrics
Total Citations48
Citations/Year8.0
Relative Citation Ratio2.16
NIH Percentile76.8%
Research Impact Scores
APT Score0.75
Weight Score2.14
Normalized Score0.63
Related Supplements
A lifestyle intervention of weight loss via a low-carbohydra... | Panacea Index